Smoking Cessation Treatment Guide

Tobacco use is the leading preventable cause of death in the United States, responsible for more than 480,000 deaths annually. Nearly 70% of current smokers say they want to quit. The gap between wanting to quit and successfully quitting is where clinical medicine has the most to offer.

What I tell every patient who comes to me about quitting: this is not a willpower problem. Nicotine is one of the most addictive substances known, and the brain changes that come with long-term smoking are real and measurable. The good news is that we have effective tools — medications that work, counseling frameworks that are practical, and a federal mandate that says these treatments should cost you nothing.

This guide covers the full evidence base for smoking cessation: what the guidelines say, how each FDA-approved medication works, why relapse happens and what to do about it, and what the science actually shows about e-cigarettes. My goal is to give you the same information I use with my own patients when we build a quit plan together.

The USPSTF 2021 Recommendation — What It Means for You

In January 2021, the U.S. Preventive Services Task Force released a final recommendation on tobacco cessation that carries significant clinical and practical weight.^[1] The USPSTF assigned a Grade A recommendation — its highest rating — to providing both behavioral interventions and FDA-approved pharmacotherapy to non-pregnant adults who use tobacco.

For pregnant persons, the USPSTF gives a separate Grade A recommendation for behavioral interventions alone, and an Insufficient (I) rating for pharmacotherapy due to limited safety data. For everyone else, the recommendation is clear: ask, advise, and treat with both medication and counseling.

The USPSTF also issued an Insufficient (I) grade on the use of e-cigarettes for cessation in adults, meaning the evidence is not adequate to recommend them. Clinicians are directed to use interventions with established effectiveness instead.^[1]

The 5 A's Framework: How Clinicians Approach Cessation

The 5 A's is the clinical framework the USPSTF explicitly endorses for tobacco cessation counseling. It can be applied in a brief office visit, a telehealth appointment, or even a structured phone call. Here's how each step works in practice:

In my practice, the "Arrange" step is the one most often skipped — and it's often the most valuable. The first two weeks after a quit date are the highest-risk period. A brief check-in call can make the difference between a relapse and a success.

Readiness to Quit: The Stages of Change Model

Not every patient who smokes is ready to quit today — and trying to force-fit a quit plan onto someone who isn't ready rarely works. The transtheoretical model (stages of change) gives clinicians a way to meet patients where they are.^[7]

Patients cycle through these stages — sometimes repeatedly — before reaching stable abstinence. Relapse does not send someone all the way back to precontemplation. Most people who relapse return quickly to the contemplation or preparation stage. That's why every quit attempt is progress, not failure.

Planning Your Quit Date

Picking a quit date is more than a formality. Research shows that having a specific quit date — typically set 1–2 weeks out — gives you time to start medication, prepare your environment, and line up support without losing momentum. Here's the framework I walk patients through:

• Pick a date within 2 weeks. Longer lead times allow motivation to fade. Shorter timelines don't allow medications to reach therapeutic effect. One to two weeks is the evidence-supported window.
• Start medication before your quit date. Varenicline is started 1–2 weeks before the quit date to allow it to reach steady state. Bupropion SR is started 1–2 weeks before quitting because it takes time to build up and reduces cravings during that pretreatment window.
• Remove cigarettes and paraphernalia from your environment. Lighters, ashtrays, and spare packs are relapse triggers sitting in plain sight. Clear them out.
• Tell the people around you. Social support predicts outcomes. Telling family and close friends also creates a layer of accountability that helps during the first difficult weeks.
• Identify your top three triggers. Common triggers include coffee, alcohol, stress, driving, and being around other smokers. Having a specific plan for each trigger — not just a vague intention — is what separates a plan from a wish.
• Have a coping strategy for cravings. A nicotine craving typically peaks within 3–5 minutes and then subsides. Short-acting NRT (gum, lozenge, inhaler) can bridge that window. So can a brief walk, deep breathing, or a glass of water.

FDA-Approved Pharmacotherapy: What Works and How

Three classes of first-line medications are FDA-approved for smoking cessation. All three have strong evidence behind them. Choosing among them depends on patient history, preferences, contraindications, and prior treatment experience.

Varenicline (Chantix) — The Most Effective Single Agent

Varenicline is a partial agonist of the alpha-4 beta-2 nicotinic acetylcholine receptor. This mechanism does two things at once: it partially stimulates the receptor (reducing withdrawal symptoms and cravings) and it blocks nicotine from binding (reducing the reward when a patient does smoke). That dual action is why it outperforms both NRT and bupropion as a single agent.

Clinical trial data, analyzed by TheNNT.com, puts the NNT for varenicline at approximately 8–11 compared to placebo — meaning roughly 1 in 8 to 11 people who complete a course of varenicline will quit who otherwise would not have.^[3] Against placebo alone, the NNT drops to about 6. These are meaningful numbers in the context of addiction medicine.

Dosing: Varenicline is started at 0.5 mg once daily for days 1–3, then 0.5 mg twice daily for days 4–7, then 1 mg twice daily from day 8 through the end of treatment (typically 12 weeks). A second 12-week course is supported by evidence for patients who quit successfully — it helps maintain abstinence. The quit date is targeted around day 8–14 of treatment.

Common side effects: Nausea is the most frequently reported side effect, occurring in up to 30% of patients. Taking varenicline with food and a full glass of water significantly reduces this. Abnormal dreams and insomnia are reported by some patients, particularly in the first few weeks. These usually improve over time.

Bupropion SR (Zyban) — The Antidepressant That Helps Smokers Quit

Bupropion SR was originally approved as an antidepressant, but its FDA indication for smoking cessation is based on its effect on dopamine and norepinephrine pathways — the same pathways that nicotine acts on. It reduces cravings and blunts some withdrawal symptoms without delivering any nicotine.

Bupropion approximately doubles the odds of quitting compared to placebo, with roughly 1 in 5 patients achieving abstinence at one year in clinical trials.^[4] It is less effective than varenicline as a head-to-head single agent, but it is a strong option for patients who cannot take or prefer not to take varenicline, or those who have a history of depression or who are concerned about mood changes during cessation.

Dosing: 150 mg once daily for the first 3 days, then 150 mg twice daily (at least 8 hours apart to reduce seizure risk). Treatment typically begins 1–2 weeks before the quit date. Standard course is 7–12 weeks, with continuation up to 6 months supported in patients who quit successfully.

Key contraindications: Bupropion lowers seizure threshold and is contraindicated in patients with a seizure disorder, current or past bulimia or anorexia nervosa, and in patients taking MAO inhibitors. It is also not appropriate during abrupt alcohol or benzodiazepine withdrawal.

Nicotine Replacement Therapy (NRT) — Five Formulations, One Principle

NRT delivers controlled amounts of nicotine through non-combustion routes, reducing withdrawal severity without the thousands of toxic compounds in cigarette smoke. All five NRT formulations are FDA-approved and available over the counter (patch, gum, lozenge) or by prescription (inhaler, nasal spray).

Combination NRT: Patch Plus a Short-Acting Form

Using a nicotine patch together with a short-acting NRT — gum, lozenge, or inhaler — is more effective than using either product alone. The patch provides a steady nicotine baseline, reducing background withdrawal. The short-acting form handles breakthrough cravings on demand.

A Cochrane systematic review found that combination NRT increases long-term quit rates by approximately 25% compared to single-form NRT (risk ratio 1.27; 95% CI 1.17–1.37), based on 16 studies and more than 12,000 participants.^[5] The CDC recommends this approach and it is consistent with the USPSTF guidance on providing proven interventions.

Cardiovascular Safety: What the EAGLES Trial Showed

For years, there was concern — based on post-marketing reports — that varenicline might increase the risk of serious cardiovascular events. This concern led the FDA to add a black box warning and drove many clinicians to avoid it in patients with heart disease. The EAGLES trial resolved that question.

What this means in practice: patients who have had a prior heart attack or stroke, who have coronary artery disease, or who are at elevated cardiovascular risk are not excluded from varenicline treatment based on cardiovascular safety concerns. Smoking itself is a major cardiovascular risk factor — helping those patients quit may be among the most important cardiovascular interventions we have.

E-Cigarettes and Vaping: What the Evidence Shows

This is one of the most common questions I get, and I want to give you a straight answer: the FDA has not approved any e-cigarette or vaping product as a smoking cessation aid. That's not a technicality — it reflects the current state of the evidence.

In 2021, the USPSTF concluded there is insufficient evidence to assess whether e-cigarettes help adults quit smoking, and specifically recommended directing patients to interventions with proven effectiveness and established safety.^[1] The National Academies of Sciences, Engineering, and Medicine (NASEM) conducted the most thorough review of e-cigarette health effects to date and found only moderate evidence that e-cigarettes with nicotine are more effective than those without nicotine for cessation — but insufficient evidence to compare them to FDA-approved treatments.

The bottom line: if you are asking whether you should switch from cigarettes to vaping as a quit strategy, my answer is to reach for a proven tool first — varenicline, bupropion SR, or NRT. If you are already vaping and asking about quitting vaping, that is a separate conversation and the same pharmacotherapy options apply.

Relapse: Normal, Expected, and Manageable

Most people who successfully quit smoking did not do it on the first try. The data consistently shows that 8–11 serious quit attempts precede long-term abstinence for most former smokers.^[6] Relapse rates in the first year are high — roughly 70–80% of people who attempt to quit will smoke again within 12 months, with the majority of relapses occurring in the first 6 months.

This is not a character flaw. It is the biology of addiction. The brain's reward pathways, restructured by years of nicotine exposure, take time to normalize. Understanding why relapse happens is the first step toward a more effective next attempt.

Common Relapse Triggers

• Stress and emotional distress — The most frequently reported relapse driver. Nicotine acutely reduces stress hormones, and the brain "remembers" that.
• Social situations — Being around other smokers, attending parties where smoking is present, or social norms in certain environments are powerful situational cues.
• Alcohol — Alcohol lowers inhibition and is strongly associated with relapse, particularly in the first few months after quitting.
• Withdrawal discomfort — Irritability, difficulty concentrating, increased appetite, and sleep disruption are real and can drive someone back to smoking for relief. This is exactly what pharmacotherapy is designed to reduce.
• Weight gain concerns — Women report willingness to gain only about 2 kg before returning to smoking; men report approximately 5 kg. Post-cessation weight gain is real and needs to be addressed proactively.

Post-Cessation Weight Gain: What to Know

Average weight gain in the year after quitting is approximately 4–5 kg (roughly 9–11 lbs).^[8] This occurs because nicotine suppresses appetite and elevates metabolic rate. When it is removed, both of those effects reverse. Weight gain tends to peak around 6–8 years post-cessation and then gradually declines.

The most important thing I tell patients about this: the health benefits of quitting smoking — including a meaningfully lower risk of lung cancer, heart disease, stroke, and COPD — far outweigh the cardiovascular risk of gaining 5 kg. Varenicline and NRT both have modest weight-suppressing effects in the short term. The most durable strategy is proactive attention to diet and physical activity during the quit period, not returning to smoking to stay thin.

After a Relapse: What to Do Next

• Do not wait. Set a new quit date within days, not weeks. The longer the gap, the harder re-engagement becomes.
• Debrief honestly. What specific trigger preceded the relapse? What time of day? What was happening emotionally? That information is clinically valuable.
• Review your medication plan. Did you use medication at full dose? Was adherence consistent? Is a different agent or combination worth trying?
• Increase support. Add a quitline counselor, a behavioral therapist, or a support group if those weren't part of the prior attempt.
• Consider extending medication duration. Longer courses of varenicline (up to 24 weeks) improve sustained abstinence in patients who respond to the 12-week course.

Behavioral Support: Quitlines, Apps, and Counseling

Medication alone works. Behavioral counseling alone works. But the combination outperforms either individually, and the dose-response relationship for counseling is real — more sessions produce better outcomes.

1-800-QUIT-NOW: The National Quitline

The National Cancer Institute's quitline (1-800-784-8669) connects callers with free, state-based telephone counseling staffed by trained cessation specialists. Services are free in all 50 states and include individualized quit plans, medication information, and follow-up calls. Studies show that quitline use increases quit rates by approximately 1.5–2x compared to no support.

SmokefreeTXT and Digital Tools

The NCI's SmokefreeTXT program delivers free automated text message support for people trying to quit. Texting QUIT to 47848 enrolls users in a 6-week program with multiple messages per day during the highest-risk period. The program is evidence-based and integrated with the 1-800-QUIT-NOW system. Smartphone apps, including Smoke Free and others, offer tracking tools, craving management exercises, and progress metrics. Evidence for app-based cessation as a standalone intervention is modest, but these tools are well-suited as adjuncts to medication and counseling.

Individual Counseling and Cognitive Behavioral Therapy

Structured individual counseling — including cognitive behavioral approaches that target automatic smoking behavior and craving responses — is effective and recommended as part of a complete cessation plan. Counseling sessions focused specifically on trigger identification, coping skill development, and relapse prevention add meaningful value beyond what medication alone provides.

Insurance Coverage, Medicaid, and Telehealth Prescribing

Because the USPSTF Grade A recommendation applies to both medication and counseling, the ACA coverage mandate is broad. For non-grandfathered private insurance plans, FDA-approved cessation pharmacotherapy and cessation counseling must be covered without cost-sharing to the patient.

Medicaid Coverage

Medicaid coverage varies by state. As of 2024, 26 states provide what is considered thorough coverage — all seven FDA-approved cessation medications plus all forms of counseling, without enrollment barriers or cost-sharing.^[9] Other states cover fewer medications or impose prior authorization requirements. The Centers for Medicare and Medicaid Services (CMS) has issued guidance encouraging states to expand cessation benefits, citing both health outcomes and cost savings from preventing smoking-related hospitalizations.

Medicare

Medicare Part D covers most FDA-approved prescription cessation medications. Medicare also covers two cessation counseling attempts per year, with up to four sessions each — eight sessions total — under Part B. These sessions can be delivered via telehealth.

Telehealth for Smoking Cessation

A telehealth visit is a clinically appropriate setting for smoking cessation counseling and prescribing. A licensed physician can conduct the full 5 A's assessment, prescribe varenicline or bupropion SR, review NRT options, and provide behavioral guidance — all via secure video. Evidence shows that telehealth-delivered cessation interventions produce outcomes comparable to in-person care.

For patients who face geographic barriers, scheduling constraints, or simply prefer the privacy of a home-based visit, telehealth removes the practical friction that often delays treatment. Cessation is most effective when it starts quickly after a patient expresses readiness. Telehealth compresses the time between that decision and having a prescription in hand.

Frequently Asked Questions